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COMMITTEES
Dear colleagues and friends,
On behalf of the Association of Nuclear Medi-
cine of Federation of Bosnia and Herzegovina 
it is my great pleasure and honor to invite you 
to the 7th Balkan Congress of Nuclear Medi-
cine that will be held in Sarajevo 9 – 12th  May 
2018 at hotel Holiday. 
The congress will gather a large geographi-
cally diverse group of participants from 
the Balkan countries, countries around and 
beyond. The focus will be the latest and rel-
evant topics in the field of Nuclear Medicine 
and Molecular Imaging. 
Other then multimodality imaging we will 
also go back to basics and bring back conven-
tional nuclear medicine as “An old lady in new 
clothes”. 
The main goal of the congress is to present the 
latest achievements and developments in clini-
cal nuclear medicine, science and technology 
to physicians, physicists, chemists, technicians, 
scientists and all the other experts who work in 
this important eld.
 
We hope to see you there.
Sincerely yours,
President of the Congress
Amela Begić, MD, PhD, Professor
To further improve general Nuclear Medicine
To improve conections with Clinical Disciplines
1. Endocrinological Diagnostics and Therapy
• Thyroid gland 
• Prostate cancer – theranostic
2. Pulmonary embolism and beyond 
• Quantitative VP SPECT as a primary tool for diagnosing PE and choice of treatment
• Importance of follow up patients with PE with VP SPECT to establish duration of therapy
• Importance of Ventilation SPECT to diagnose other cardiopulmonary diseases beyond PE
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19:00-19:15  Increased patient participation through better education on nuclear and 
radiological examinations; Ronald W.J. van Rheenen
19:15-19:30  Quality Assurance in the NM department, Martin Lema 
19:30-19:45  Preclinical studies in development of therapeutic radiopharmaceuticals - the 
critical approach for successful clinical application, Emilija Janevik
19:45-20:00 PET/MRI Clinical application, Dinko Francheski 
20:00 Welcome reception
 10.05.2018.,  Thursday 
SESSION 2 THYROID GLAND part 1
Chairpersons:  Nejra Latić, Jasna Mihailović, Ioanis Iakovou
09:00-09:10  Diagnosis and management of thyroid nodules - thyroid cancer overdiagnosis, 
Maja Franceschi 
09:15-09:25 Thyroid Scintigraphy an always modern Lady, Savvas Frangos 
09:30-09:40  Role of SPECT-CT Images in the Management of Thyroid Disorders”,  
Sonya Sergieva 
09:45-09:55  Parathyroid scintigraphy in patients with primary hyperparathyroidism,  
Silvija Canecki Varžić
10:00-10:15 Discussion 
10:15-10:45 Coee break
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10:45-10:55  Management of dierentiated thyroid cancer-facts and controversies,  
Jasna Mihailović 
11:00-11:10  Diagnostic and therapeutic modalities in patients with refractory DTC,  
Elma Kučukalić-Selimović 
11:15-11:25  Personalized approach in tailoring radioiodine therapy for thyroid cancer,  
Ana Ugrinska 
11:30-11:40  PRRT in patients with iodine-negative thyroglobulin-positive thyroid cancer, 
Marina Vlajković 
11:40-11:55 Discussion
SESSION 4  TECHNOLOGY, RADIOPHARMACY AND PHYSICS 
Chairpersons:  Martin Lema, Adnan Beganović, Nusret Salkica
11:55-12:05  Current Good Manufacturing Practice with integrated Building Management 
System in the production of PET Radiopharmaceuticals, Emilija Janevik 
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 11.05.2018.,  Friday 
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Ari Lindqvist
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11:35-11:45  Radionuclide brain perfusion & metabolism imaging in the diagnosis of 
dementia, Qaisar Siraj
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Piperkova
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first proof of principle for alpha targeted treatments, Sabina Dizdarević 
13:45-13:55  Theranostics and Molecular Radiotherapy for Metastatic Prostate Cancer, Bengul 
Gunalp 
13:55-14:10 Discussion
14:10-15:20 Lunch
SESSION 8 THERANOSTIC part 2
Chairpersons:  Dražen Huić. Marina Hodolić, Fani Bozgurt
15:20-15:40 Theranostics with PSMA ligands in prostate cancer, Zehra Ozcan
15:45-15:55 Theranostic of Prostate Cancer with Radiometallic Agents, Adriano Duati 
16:00-16:20 PET/CT in gastro-esophagial cancers, Omer Ogur
16:25-16:35 Unresectable liver tumors: Y-90 microspheres therapy, Vassilios Prassopulos 
16:40-16:50  Comparison of imaging methods for diagnosis and follow-up of bone 
metastases, Marina Garcheva 
16:55-17:10 Discussion
18:30 Departure for the dinner with sightseeing of Sarajevo
20:00 Congress dinner
23:00 Return to hotel Venue
 12.05.2018.,  Saturday 
SESSION 9  NET and Endocrinology
Chaipersons:  Bengul Gunalp, Timur Cerić, Ivan Mihaljević
09:00-09:20   Is there still a role for somatostatin receptor scintigraphy in the PET/CT era,  
Vera Artiko
09:25-09:35   The Impact of Molecular Imaging in Decision-Making of Therapeutic Options 
for Neuroendocrine Tumors, Fani Bozkurt
09:40-09:50   PET imaging of Diabetic Foot, Dinko Franceschi
09:55-10:10  Discussion
SESSION 6  Cardiology
Chairpersons:  Mirza Dilić, Maria Koutelou, Elena Piperkova
10:10-10:20   Myocardial perfusion imaging in the evaluation of patients with diabetes 
mellitus, Raluca Mititelu
10:25-10:35   Role of FDG PET/CT in diagnosis and follow up of Endocarditis,  
Dragana Šobić Šaranović
10:45-11:05   Courage, Fame and Death – CARDIOLOGY, Pushan Bharadwaj
11:05-11:15   The assessment of viable myocardium with 99mTc MIBI SPECT in patients with 
dilated myocardiopathy, Amra Čičkušić Jakubović
11:20-11:30   Regadenoson: A new stress test agent for Myocardial Perfusion Imaging,  
Maria Koutelou
11:30-11:45  Discussion
 
12:00 Closing ceremony
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P001
Regadenoson myocardial perfusion imaging: Performance and safety prole based on 1-year 
institutional experience in Greece.
Authors: Koutsikos J, Angelidis G, Velidaki A*, Vogiatzis M, Ilia E, Zaxaki S., Mamarelis I**, Lazaridis 
K**, Zafeirakis A, Demakopoulos N
E-mail: jtkoutsik@yahoo.gr
Department of Nuclear Medicine, Army Share Fund Hospital,* Department of Nuclear Medicine, 
Laiko General Hospital, **Department of Cardiology, Army Share Fund Hospital. Athens, Greece
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
Background / Aims: Regadenoson is a selective A2A adenosine receptor agonist recently 
approved for clinical use in Greece. Similarly to other adenosine receptor agonists, regadenoson 
may cause several side-eects after its administration in patients undergoing regadenoson 
myocardial perfusion imaging (MPI). We investigated the performance and safety prole of 
regadenoson MPI based on our 1-year institutional experience. 
 
Methods: We enrolled 133 consecutive patients (82 males, 51 females, mean age 69.6 y.o) referred 
to the Department of Nuclear Medicine at the Army Share Fund Hospital (417 NIMTS), Athens, 
Greece, for a clinically indicated pharmacological stress MPI. All participants were ≥20 years of age 
without meeting any of the contraindications to regadenoson administration.
18 patients suered from chronic obstructive pulmonary disease (COPD). All participants 
underwent regadenoson stress test, combined with both stress and rest MPI. Data on the 
symptoms and electrocardiographic changes, observed due to regadenoson administration, 
were recorded. Symptoms were graded as 1-mild: a symptom that did not distress the patient, 
2-moderate:
a symptom that distressed the patient but it was self-limiting, or 3-severe: a symptom that 
distressed the patient requiring medical intervention 
Results: 80 patients had abnormal MPI studies. Regadenoson-related symptoms were reported in 
79 patients. The three most common symptoms were dyspnea (38/133), discomfort (20/133), and 
dizziness (17/133). The severity of symptoms was recorded as grade 1 in 41 patients, grade 2 in 37 
patients, and grade 3 in 1 patient. Two or more dierent symptoms were reported in
38 patients. Ischemic electrocardiographic changes and arrhythmias were observed in 14 patients. 
Conclusions: Our ndings support previously published data regarding the safety prole of 
regadenoson MPI. Symptoms were common, but transient, requiring medical intervention in only 
one case. Dyspnea was found to be the commonest side-eect; however, the procedure was well 
tolerable, even in COPD patients.
POSTER ABSTRACTS
P002
The relationship between illness perception and quality of life in thyroid patients who received 
radioiodine ablation treatment
Authors Akyildiz G, Elboga U, Sayiner ZA,Elboga G
E-mail: umutelboga@hotmail.com
Gaziantep
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
Aim:We aimed to evaluate this on Turkish thyroid cancer patients who had radioiodine treatment 
after total thyroidectomy.
Methods:A total of 100 patients were recruited in this cross-sectional study. Patients’ age, 
educational level, marital status and disease characteristics including stage, treatment and follow-
up period since diagnosis were noted. Short Form 36 Health Survey Questionnaire, The illness 
Perception Questionnaire was used to assess the quality of life and illness perception, respectively. 
Statistical significance of the associations were analyzed using Shapiro-Wilk Test, Student’s t, Mann 
Whitney u, and ANOVA tests.
Results:The mean age of patients enrolled in the study was 40.62. There were 84 (84.0%) female 
and 16 (16.0) male cases. 72 cases reported that they experienced loss of strength, 60% of whom 
associated the symptom with disease. When we correlated the illness perception sub-scales and 
quality of life dimensions in our study, the most apparent negative correlation was seen between 
the immunity dimension of the disease sub-scale and quality of life sub-dimensions. There 
was also a negative and significant (p<0.05) correlation between the dimensions of ability to 
understand the disease and overall health; emotional representations dimension, and vitality and 
overall health dimensions under quality of life, and causes of the disease and all sub-dimensions 
of quality of life.
Conclusion:The fact that the patients believe that their body resistance is low have a remarkably 
lower quality of life, and patients’ ability to understand the disease is strikingly low clearly show 
the effect of the way of perception of illness in patients on the quality of life. 
P003
THE EFFECTS OF 131-I-MIBG THERAPY IN ADVANCED MEDULLARY THYROID CARCINOMA
Authors: Mihaljević I, Šnajder D, Topuzović N, Wagenhofer V, Kralj T, Mudri D, Mijatović K. 
E-mail: ivanm2712@gmail.com
Clinical Institute of Nuclear Medicine and Radiation Protection, University Hospital Osijek, Croatia. 
Faculty of Medicine Osijek, Josip Juraj Strossmayer University of Osijek, Croatia.
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
Aim: The effects of 131-I-metaiodobenzylguanidine (MIBG) therapy on the survival of patients 
with advanced medullary thyroid carcinoma (MTC) were investigated. Long-term survival of 
patients with disseminated MTC remains largely unsatisfactory mainly because current irradiation 
and chemotherapy treatment commonly fails to defeat the disease. 131-I-MIBG may provide 
additional therapeutic benefits. Methods: Therapeutic doses of 100 mCi (3.7 GBq) 131-I-MIBG 
were administered by slow i.v. infusion to 7 patients (5 female and 2 male aged 18 to 80 years) 
with proven disseminated MTC. All patients underwent a total thyreoidectomy and selective neck 
dissection prior to the treatment, and distant metastases were diagnosed. The total therapeutic 
doses the patients received ranged from 3.7 to 18.5 GBq of 131-I-MIBG in 3 months to 1.5 
years intervals. All patients tolerated the treatment well. Tumor marker levels (calcitonin-hCt, 
carcinoembryonic antigen-CEA, neuron specific enolase-NSE, chromogranin A-CgA, pro-gastrin 
releasing peptide-pro-GRP) were measured before and after therapy. Whole body scintigraphy 
performed after the therapy showed indication of metastatic disease. Results: In four patients 
we observed a decrease in hCt level, in one case the decrease lasted for 6 months, and in one 
patient the increase in hCt level appeared 10 months after the therapy, and in one patient no lung 
metastases were visible on whole body scan after the second 131-I-MIBG therapy. Other two cases 
showed a significant decrease in tumor marker levels only after the neck dissection, but after that 
further dissemination was observed. Conclusion: The effects of hCt tumor marker levels reduction 
after 131-I-MIBG therapy in patients were temporary and individual. MTC metastases can be 
partially reduced in certain cases.
According to our experience, the objective response to 131-I-MIBG therapy is limited, but it can 
improve patient survival.
Main topic: 1. Endocrinological Diagnostic and Therapy Key words: medullary thyroid carcinoma, 
I-131-MIBG therapy
P004
2-[18F]FLUORO-2-DEOXY-D-GLUCOSE PRODUCTION: CORRELATION BETWEEN YIELD AND EOB 
ACTIVITY
Authors: Chochevska M., Atanasova Lazareva M., Kolevska K., Velichkovska M., Jolevski F., Razmoska 
J., Doslakoski N., Filipovski Z., Nikolovski S., Zdraveska Kocovska M., Janevik Ivanovska E.
E-mail: maja.cocevska@ugd.edu.mk
University Institute for Positron emission tomography, Skopje, Republic of Macedonia
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
2-[18F]fluoro-2-deoxy-D-glucose ([18F]FDG) production is a routine synthesis process, involving 
fully automated synthesizer with single-use disposable system - integrated fluidic processor (IFP 
cassette) and overall synthesis time of 30 minutes. The synthesis of [18F]FDG is a six-step process 
consisting of two chemical reactions, a nucleophilic 18F- fluorination followed by a base-catalyzed 
hydrolysis. 18F- is produced by irradiating enriched [18O]-water with protons with GE PETtrace 
16.5 MeV cyclotron, at University Institute of Positron Emission Tomography, Skopje.
The amount of starting radioactivity depends on the desired radioactivity
of final product, so because of that, our objective was to determine
whether amount of starting radioactivity affects the radiolabeling
efficiency and the capacity of starting materials or the production yield.
Forty batches of [18F]FDG were produced with same IFP cassette and the same
reagent kit (different batch production but same producer). 
The mean decay corrected production yield for [18F]FDG produced by starting
radioactivity of 18F- from 20-35 GBq, 55-75 GBq and 150-170 GBq were 71,44%
± 5,5%, 70,13% ± 5,5% and 67,11% ± 2.3%, respectively. The results
confirm that the starting radioactivity of radioisotope does not affect the
production yield and there is no significant difference between the results
in these three groups of results, p>0.05 (0.069). [18F]FDG was successfully
synthesized with a production yield above 60% in all batches, as result of
the high-quality and the large capacity of starting materials for
radioactivity to give efficient radiochemical synthesis.
P005
VALIDATION OF CHEAP, FAST AND EFFICIENT METHOD FOR DETERMINATION OF KRYPTOFIX IN 
[18F] FDG RADIOPHARMACEUTICAL USING IODINE VAPOURS
Authors: Jolevski F., Velichkovska M. , Atanasova Lazareva M. , Chochevska M. , Kolevska K. , Janevik 
Ivanovska E. 
E-mail: filip.jolevski@ugd.edu.mk
University Institute for Positron emission tomography, Skopje, Republic of Macedonia
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
The commonly used phase transfer catalysts in production of 18F-Fludeoxyglucose ([18F]FDG) is 
Kryptofix 222. Because of its toxicity, quality control is performed before the administration of this 
radiopharmaceutical, to be sure that the limit concentration is not reached and the preparation is 
safe for administration in patients.
Our purpose was to optimize a method using iodine vapours for determination of Kryptofix 222 
that is cheaper, faster and reliable than the method described in monograph of [18F]FDG in 
European Pharmacopoeia, to prove its specificity and determine the limit of detection (LOD).
Materials and equipment: Silica Gel TLC plates, iodine ACS, Kryptofix standard, saline , Water type 1, 
standards of FDG, CLDG and FDM, Glucose, pipettor, tips, glass chamber.
In our TLC procedure 4 µl of solution was applied to silica gel TLC, and after drying the plate was 
exposed to iodine vapours for 5 min in a chamber. 
For determination of the specificity we prepared two matrix solutions that contained FDG, 
FDM, ClDG and glucose dissolved in saline (Matrix 1) and water type 1 (Matrix 2). There was no 
significant coloration/discoloration when they were compared with saline/water type 1. The spot 
with Kry dissolved in Water Type 1 was more intensive compared with Kry dissolved in saline. For 
more comparable conditions to our product of synthesis, in the following steps in determining 
the LOD, Kry standard solutions were prepared in saline. LOD for this method was 6.125 µg/ml. 
When we applied different series of produced FDG from period of 6 months we confirmed that 
quantity of Kry was significantly below the determined LOD of this method.
A cheap, fast, easy to handle, efficient spot-test method for semi-quantitative analysis of Kry 
was optimized and validated for specificity and LOD, and can be used in routine analysis of our 
production of FDG radiopharmaceutical.
P006
WHO REALLY NEEDS BONE SCINTIGRAPHY IN INITIAL STAGING AMONG THE PATIENTS WITH NEWLY 
DIAGNOSED PROSTATE CANCER
Authors: Ljiljana Jaukovic, Marija Radulovic, Sanja Dugonjic, Marija Sisic
E-mail: lilaj2805@gmail.com
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We included 818 patients with previously untreated prostate cancer (PCa) who underwent bone 
scintigraphy at a single institution between 2010 and 2017.
The purpose of this study was to determine whether serum prostate specific antigen (PSA) and 
total Gleason score (GS) on biopsy can predict osseous metastases and eliminate the need for a 
bone scan as a routine procedure in initial staging.
Methods: Logistic regression models were used to test the relationship among the available 
predictors and bone metastases on scintigraphy.
Results showed that 182 of all bone scans (22.3%) were positive for metastases. This proportion 
was significantly higher in patients with PSA>20ng/mL (41.8%) vs. PSA<10ng/mL (9.5%). The 
proportion of positive
scintigraphy findings was significantly lower in patients with GS≤6 (12.9%) vs. GS≥9 (49.4%). There 
was no statistically significant difference in age between patients with bone metastases (BM) 
vs. patients with no BM (P >0.05). In univariate analysis, PSA level (p<0.001) and biopsy Gleason 
score (p<0.001) were strongly correlated with bone scan positivity. PSA level >20ng/mL enhanced 
the chances of metastatic bone involvement by 6.8 fold using the PSA<10ng/mL as the referent 
category.
Similarly, patients with GS≥9 had 6.6 fold more chances to show bone metastases than patients 
with GS≤6. On multivariable analysis, increasing PSA level (p<0.001, OR 2.37; CI: 1.798- 3.036), 
and increasing biopsy Gleason scores (p<0.001, OR 1.93; CI: 1.403- 2.665) were still independent 
predictors of BM.
Conclusion: Men presenting with PSA values of<10ng/mL and GS≤6 should safely avoid 
unnecessary bone scintigraphy in initial staging of prostate cancer.
Key- words: Prostate cancer, predictors ,bone metastases
 Oncology: Diagnostic and Treatment
P007
Effective dose of for medical workers during Y-90 microspheres radioemblization
Authors: K Dalianis,G Kollias, F. Vlachou, T. Pipikos, R Euthimiadou, J Andreou, V Prassopoulos.
E-mail: kdalianis@hygeia.gr
Nuclear Medicine Department Hygeia Hospital, Athens, Greece
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
Introduction
Due to the increasing need for radioemblization of liver cancer with Yttrium 90 microspheres a 
new need for evaluation of the radiation exposure of the medical staff is necessary. The objective 
of this study is to assess occupational exposure for nuclear medicine, radiology and clinical staff 
involved in Y90 preparation and implantation. Although there are guidelines and regulation 
regarding the use of radioisotopes for therapy when a new teaqnic is used for first time new 
measurements should be perform in order to reduce the occupational radiation doses to the 
workers.
Material & Method
To estimate the effective dose from external exposure the nuclear medicine physician and the 
medical physicist had electronic dosimeters and TLD badges worn at the upper pocket of their 
overall, TLD rings on the second finger of each hand. The basics stages for radioemblization 
procedures involve 3 steps: measuring the Y-90 vial, segmentation of the dose, transport to 
radiology, implantation of the radiopharmaceutical.
Results
The results of our study for the average cumulative whole body dose for 22 patients (μSv±SD) at 
different stages were: measuring the Y-90 vial, segmentation of the dose, transport to radiology, 
132±7,23 (Medical
Physicist) , implantation of the radiopharmaceutical 197±6,67 (Nuclear Medicine Physician) . The 
mean finger exposures for the Medical Physicist were 132 ± 76 μSv/GBq. For administration of resin 
microspheres, mean finger exposures for the Nuclear Medicine Physician were 197.5 ± 90 μSv/GBq.
Conclusion
Medical staff performing radioembolization procedures is exposed to safe levels of radiation. 
The personnel dose results are significantly lower than the recommended annual dose by 
International Commission for Radiological Protection. However a greater effort should be made to 
reduce the doses further in line with the ALARA principle.
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Purpose: Although testicular cancer is a common cancer, affecting as well younger male, its 
prognosis remains excellent with 5 year survival rate over 90%. CT is the image of choice for 
staging and restaging the disease.
However, CT has the limitation of anatomical imaging and the criterion of size when evaluating 
residual enlarged lymph nodes. On the other hand, chemotherapy is not innocent of 
complications and attention should be paid when administered especially in young patients. The 
aim of this study is to examine the role of PET/CT in evaluating treatment response in testicular 
cancer patients. 
Method-Material: 83 patients 17- 56 y.o suffering from testicular carcinoma underwent 86 PET/
CT examinations for restaging their disease after treatment and evaluation of therapy response. 
60 min after the IV administration of 18F-FDG, PET/CT was performed at a Siemens Biograph LSO 
device. PET images were reconstructed at three levels, corrected for attenuation and fused with 
CT. All patients had previously been restaged by conventional imaging (CT). Comparison of the 
two imaging modalities took place. Patients were followed up for 1year.
Results: PET/CT was positive in 27/86 cases and negative in 57/86. In 23/27 cases both PET and 
CT were positive; however PET revealed more metastatic lesions in 4 cases, concerning lymph 
node invasion. In 4/27 cases CT was negative while PET showed residual disease, 1 osseous and 3 
lymph node metastasis. 27/57 cases both PET and CT were negative and in 30 cases CT was either 
positive or equivocal (small pulmonary lesions, lymph nodes slightly enlarged) while PET was 
negative for hypermetabolic lesions. In 2/86 cases both PET and CT showed equivocal findings. 
Conclusion: PET/CT is a whole body imaging modality, can be hepful in estimating treatment 
response and evaluating residual lesions on CT, since functional alterations precede the 
anatomical ones. However, attention should be paid at small pulmonary nodules that do not 
present hypermetabolic activity.
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Purpose: Solid pulmonary nodules (SPN) are one of the major indications for performing PET/
CT examination, with high accuracy in characterizing nodules >1cm as benign or malignant. 
However smaller nodules, as well as well differentiating and specific histologic types that 
accumulate FDG in a less degree and inflammatory processes can provoke differential diagnostic 
problems and lead to further unnecessary examinations. In this study we examined the possible 
role of delayed PET acquisition in addition to standard PET in characterizing SPN. 
Method- Material: 17 patients, 7 female average 54y.o., 10 male average 66y.o. were included in 
the study. 8 presented with SPN ≤1cm, 6 with SPN 1-2cm and 3 with SPN>2cm. 60min after the 
IV administration of 18F-FDG PET/CT was performed at a Siemens LSO Biograph PET/CT device. 
60min after the first acquisition, delayed data of pulmonary fields were acquired. The size of the 
nodule, the uptake of the radiopharmaceutical (SUVmax) at the first and delayed acquisition were 
evaluated. For all patients histologic confirmation or 6 month surveillance was available.
Results: In 8 patients with SPN≤1cm, mean first SUVmax was 1.7 and mean delayed SUVmax 
2.1. 1 nodule did not accumulate FDG at both first and delayed images and proved benign. 1 
nodule presented with SUVmax 1.2 at first and 1.5 at second PET, however due to morphologic 
characteristics of the nodule, the patient was put under surveillance and no further therapeutic 
action was taken. For 6/8, the delayed SUVmax was higher than the first, with increase 1-1.38 folds 
and the final diagnosis was adenocarcinoma. In 6 patients with SPN 1-2cm, mean first SUVmax 
was 1.97 and mean delayed SUVmax 2.75. In 2 cases delayed SUVmax decreased and patients 
were put under surveillance, while in the rest 4 delayed SUVmax increased by 1.2-1.9 folds. Final 
diagnosis for these 4 patients was neuroendocrine tumor for 2 and adenocarcinoma for 2. In 3 
patients with SPN>2cm, mean first SUVmax was 4.8 and mean delayed SUVmax 6.1, raise of
1.28-1.48folds and final diagnosis was adenocarcinoma. Degree of SUVmax alterations was not 
correlated with the grade; however this is justified considering the low tumor volume.
Conclusion: Delayed imaging can contribute to the differential diagnosis of SPN, particularly 
in small <1cm pulmonary nodules and in further management of the patients. Although 
morphologic appearance of the nodule should not be overlooked, increase of FDG uptake is 
correlated with malignancy, while decrease with benign condition. 
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Purpose: The aim of this study is to assess the value of In-111-Octreotide SPECT/CT imaging 
in staging and restaging patients with neuroendocrine tumors and its impact in interobserver 
variability during interpretation of the images.
Method-Material: 25 patients, with neuroendocrine tumor underwent 111-Octreotide 
scintigraphy, for initial staging or after clinical and/or biochemichal evidence of relapse. Whole 
body imaging was performed at 4 and 24h after the IV administration of 185MBq In-111-
octreotide. Static and tomographic views of brain, thorax, abdomen and pelvis were obtained at 4,
24 and, when necessary, 48h. Images were blinded and reviewed by two experienced nuclear 
medicine physicians (NM). A third reader, an experienced radiologist, provided consensus in cases 
of disagreement of the exact location of the findings. Consensus was therefore achieved in cases 
of disagreement. However interobserver variability was a major question of the study and was 
searched. Results were scored 0-3, 0 for negative study, 1 for equivocal (surgical incision, intestinal 
activity), 2 for CT lesions only, 3 for lesions with increased uptake of the radiopharmaceutical. 
Results: Final consensus SPECT/CT results: 12 patients were scored as 0 and 5 as 1. 7 patients 
were scored as 3: liver, brain, peritoneal implantations, supraclavicular and abdominal lymph 
nodes. In one case CT revealed consolidation of the upper left pulmonary lobe, however without 
accumulation of the radiopharmaceutical. This patient presented additionally with invaded lymph 
nodes (score 3). In one case, accidental finding at the breast presented at CT only (score 2) proved 
to be breast cancer. Final consensus planar results: 17 patients were scored as 0, 4 as 1 and 4 as 3. 
Agreement between NM readers was reached for liver lesions >1.5cm, liver cysts, thyroid nodules 
>5mm, brain lesions, surgical incisions and breast lesion. Disagreement was noticed for small liver 
lesions located near the gallbladder- for which the radiologist added his experience-, peritoneal 
implantations and abdominal lymph nodes <8mm. In total, agreement was reached for 20/25 
patients (80%) when only planar images were reviewed, which increased to 23/25 (92%) with 
SPECT/CT.
Conclusion: Hybrid In-111-octreotide SPECT/CT has a promising role in identifying lesions with 
somatostatin receptors and in the management of patients with neuroendocrine tumors, with 
higher diagnostic accuracy compared to only planar imaging. Interobserver variability is minimal 
when SPECT/CT images are interpreted compared to only planar imaging, due to more precise 
tumor localization and identification of physiologic activity.
Accidental findings on CT can also be identified.
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Purpose: Hybrid In-111-Octreotide SPECT/CT imaging is a promising procedure for the study of 
neuroendocrine tumors. While planar images can only vaguely discriminate the localization of 
invaded sites and physiologic uptake of the radiopharmaceutical is often mistaken for sites of 
disease, SPECT/CT provide fusion of functional and anatomic imaging in one device.
The aim of this study is to assess the incremental value of In-111-Octreotide SPECT/CT imaging in 
the initial staging and restaging patients with neuroendocrine tumors.
Method-Material: From January 2011 to March 2012, 25 patients -12 male and 13 female, aged 
35 to 72 y.o.- with diagnosed neuroendocrine tumor underwent 111-Octreotide scintigraphy, 
either for initial staging of their disease or after clinical and/or biochemichal evidence of relapse. 
Whole body imaging was performed at 4 and 24h after the IV administration of 185MBq In-111-
octreotide. Static and tomographic views of brain, thorax, abdomen and pelvis were also obtained 
at 4, 24 and when necessary 48h.
Images were reviewed by two experienced nuclear medicine physicians (NM).
Results were scored 0-3, 0 for negative study, 1 for equivocal (surgical incision, intestinal activity), 2 
for CT lesions only, 3 for lesions with increased uptake of the radiopharmaceutical.
Results: According to SPECT/CT 7 patients were scored as 3: liver, brain, peritoneal implantations, 
supraclavicular and abdominal lymph nodes enriched with somatostatin receptors. In one case 
consolidation of the upper left pulmonary lobe did not accumulate the radiopharmaceutical 
(score 2); however the patient presented additionally with invaded lymph nodes (score 3). In one 
case a finding at the breast presented at CT only (score 2) proved to be breast cancer. 5 patients 
were scored as 1 and 12 as 0.
According to only planar imaging 4 patients were scored as 3, 4 as 1 and 17 as negative. The 
effective dose estimated for the In-11-octreotide scintigraphy is 26mSv. Additionally the patient 
receives 5-8mSv, depending on patient’s height, from CT, when SPECT/CT is acquired. 
Conclusion: Our preliminary data suggest that Hybrid In-111-octreotide SPECT/CT has a promising 
role in identifying lesions enriched with somatostatin receptors as well as in the management of 
patients suffering from neuroendocrine tumors, with adding only small amount of radiation to 
the patient. SPECT/CT provides more accurate tumor localization, as well as the identification of 
physiologic activity. Moreover accidental findings on CT should, also not overlooked. 
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Abstract
Renal cell carcinoma is the most common solid tumor of the kidneys. It accounts about 3% of all 
malignances and representing a seventh leading cause of cancer. PET/CT has appeared as hybrid 
modality imaging in staging, restaging, detecting metastases and monitoring the response of 
therapy in most malignant diseases. 
The usefulness of F18 FDG PET/CT still remains unclear and has a limited role in evaluating of 
RCC and it is not recommended in national guidelines as a method of choice. However in the 
literature there are more and more reports where F18 FDG PET/CT might be effectively used for 
postoperative surveillance, restaging and early assessment of recurrent/metastatic disease and 
affect therapeutic decisions in mRCC patients. There is report by Kayani et al. a cohort study of 44 
mRCC patients treated with Sunitinib that a metabolic response by F18 FDG PET/CT at 4 weeks 
didn’t correlate with outcomes, while metabolic progression at 16 weeks was predictive of inferior 
survival. Our institution has had one patient case of mRCC where F18 FDG PET/CT was performed 
and used in treatment planning after surgery.
Also follow up multimodality PET/CT imaging will be performed and presented in treatment 
monitoring after Sunitinib (Sutent; Pfizer, New York, NY) therapy, an investigational multi targeted 
TKI that specifically inhibits, receptors for both vascular endothelial and platelet growth factor.
F18 FDG PET/CT might be helpful tool and has a great potential for the early evaluation of 
response to sunitinib in mRCC. Further investigation has to be performed on larger number of 
patients and protocol has to be standardized. It worth to recommend that in near future FDG PET/
CT should be incorporate in routine standard protocols for mRCC
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Introduction: Epitheloid hemangioendothelioma is an uncommon vascular tumor of intermediate 
malignant potential. This tumor can affect multiple organs (lungs, liver, bones and soft tissue, skin, 
heart, central nervous system) but lung and liver represent two main locations. Hepatic epitheloid 
hemangioendothelioma, a rare sarcoma of the liver, usually appears as multiple nodules involving 
both hepatic lobes, and can be misdiagnosed as metastatic carcinoma on the basis of its 
radiologic manifestations. Case report: A 16 years old patient was presented with a cough, febrile 
syndrome and gastroenterocolitis. CT with contrast showed focal changes in the liver and diffuse 
nodular changes in both lungs. Ultrasonography examination on the abdomen shows multifocal 
echogenic lesions in the right lobe of the liver. An ultrasound guided biopsy was performed of a 
segment 4 lesion which confirmed an epitheloid hemangioendothelioma.The patient received 
7 cycles of chemotherapy with Paclitaxel and Carboplatin. To assess treatment response and 
to guide further treatment, a whole body PET-CT scan was performed. Scan acquisition was 
3 minutes per bad on a SIMENS Biograph 40 following administration of 347MBq of 18F-FDG, 
manufactured “in house” in our GMP facility which houses a GE PET trace Cyclotron. Pre scan 
glucose was 5.4 mmol/l. PET-CT showed bilateral small parenchyma lung nodules of varying size, 
some with calcifications but with no significant increased metabolic activity. Hypodense lesions 
in the liver of varying size showed low grade increased metabolic activity with SUVmax = 2.7, just 
above than the normal liver. (SUVmax liver=2.2).Low grade increased activity (SUV max = 1.4) was 
also seen in a lytic lesion at the distal left fibula measuring 1.7x 3.7cm. From the findings of the 
lung, liver and bone lesions, we can speculate that 18F-FDG uptake is related to the grade of
malignancy.Conclusion: We present a rare PET-CT finding in a patient with hepatic epitheloid 
hemangioendothelioma and highlight the utility of PET CT scan as a useful imaging tool in this 
not very common disease. PET CT provides the capability of whole body imaging (head to toe) for 
anatomical and functional staging and can find additional lesions from conventional imaging as 
well as guide management.
Key words: epitheloid hemangio-endothelioma, PET CT, liver
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Purpose: to show a case of respiratory image misregistration during performing total body PET CT 
scan in patient with malignant melanoma.
Material and methods: a 43 yr old female after a dissection of the tumor mass in the upper part of 
the lower left limb and histopathology findings in addition to metastases of malignant melanoma 
was sent for PET CT re-staging. PET CT scan was performed from the vertex of the skull to the 
feet, with the arms along the sides of the body, 3 minutes per bad on a SIMENS Biograph 40 
PET-CT one hour after intravenous administration of 10 mCi (370Mbq) of 18F-fluorodeoxyglucose. 
18F-FDG was manufactured in house in our GMP facility which houses a GE PET trace Cyclotron. 
Pre scan glucose was 5.2 mmol/l. CT scans were acquired without intravenous or gastrointestinal 
contrast. Results: Highly metabolically active lesions in addition to the dissemination of the 
primary disease were seen: in the left inguinal region (mass d ~ 16mm/ SUVmax=11.4) in the an 
upper part of the lower left limb medially intramuscular ( mass d ~ 4x3 cm /SUVmax = 10.1,) and 
in the proximal part of the left tibia (SUVmax=6.1) In the segment 4 of the left lobe of liver there 
was high metabolic active lesion (SUVmax=16) who do not correspond with CT for attenuation. 
On simultaneous display of both Computed Tomography Attenuation Corrected (CTAC) and 
noncorrected PET images hypermetabolic lesion in the liver correspond to hypodense lesion
d=2.9x2.4 cm. However, we suggest correlation with MRI of liver due to the fact of metabolic 
active solitary lesion in the liver. Conclusion: The possibility of mis registrations in a PET CT total 
body imaging (head to toe) primarily are due to the longtime acquisition. We suggest regularly 
using a breath-hold acquisition technique during performing total body PET CT scan i.e using 
end-expiration breath-hold CT and free-breathing PET to minimize a respiratory image mis 
registration and lesion distortion. 
However, to improves image quality and image accuracy and to avoid possible pitfalls the 
simultaneous display of both Computed Tomography Attenuation Corrected (CTAC) and non 
corrected PET images, side by side with CT images is strongly recommended.
Key words: PET CT, misregistration, artefact; 
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PURPOSE: The first PET CT study in the Public Health System in the Republic of Macedonia was 
performed in June 2017. Our purpose is to show the experience from the very beginning with 
fluorine 18 fluorodeoxyglucose positron emission tomographic (PET) and computed tomographic 
(CT) scans routinely obtained in oncology patients and for staging and restaging of disease in 
patients with Hodgkin and non-Hodgkin lymphoma in a Health Public System in Republic of 
Macedonia. MATERIALS AND METHODS: We analyzed the data of all the 378 patients scanned 
in the first 3 months. There were 163 patients from the hematology department (mean age, 51 
years) with Hodgkin disease (n =49), non-Hodgkin lymphoma (n =60) and other hematology 
disorders ( 54). A further 215 patients were oncology patients, (mean age, 52 years), with a variety 
of neoplasm: breast cancer, 80 (37.7%), lung cancer, 21 (9.9%), rectal cancer, 20 (9.4%), melanoma 
18 (8.4%), colon cancer 15(7.1%), malignant neoplasm from unknown nature 13 (6.1%) and 
malignant neoplasm of other connective and soft tissue, 7 (3.3%). All patients underwent PET-CT 
scan on a BiographTM mCT-40 PET*CT scanner 60 minutes following an injection of 370 MBq of 
18F FDG (fluorodeoxyglucose).
Each dose was measured prior to the application on a Capintec dose calibrator. Whole body 
acquisition from the skull vertex to the upper tight (toes for melanoma and sarcoma) was 
performed at 3 minutes per bed position. 18F FDG was manufactured in our GMP facility which 
houses a GE PET trace Cyclotron. RESULTS: 86 of the patients with Hodgkin disease or high-grade 
non-Hodgkin lymphoma did not have previous baseline PET-CT scans. Most indications (95%) 
for oncology patients were for re-staging with already known metastases from primary diseases. 
Reporting was performed jointly by an experienced nuclear medicine physician and radiologist. 
Some of the results were interpreted after supervision of the experts in PET-CT from International 
Atomic Energy Agency. The results were sent to the referring physician within three working days. 
Although imaging guidelines were present, in the very beginning there were many oncology 
patients with non-appropriate indication. Most of patients with lymphoma were sent from 
hematologists experienced in PET-CT. There were, however, some problem in the interpretation 
of these scans due to lack of baseline pre-therapy scans. CONCLUSION: PET-CT has been a very 
useful addition to the other diagnostic imaging modalities for hematology and oncology patients 
in the Health Public System in the Republic of Macedonia. From our first experience and initial 
steep learning curve we would suggest that the nuclear physicians should be involved integrally 
from the project planning stage and work more closely with the requesting physicians and Tumor 
boards or Advisory Committee. We also concluded that every PET-CT center should maintain a 
collaboration with other experienced nuclear medicine centers or with experts from the IAEA as a 
“gold standard” to minimize unforeseen problems that arise during performing or interpretation of 
PET CT study. 
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PURPOSE:
The purpose of our retrospective study was to investigate the efficacy of 18F-FDG PET/CT in the 
detection of residual/recurrent tissue in the follow-up of patients with ovarian cancer whose 
serum Ca-125 level is rising. 
MATERYAL and METHODS:
24 patients with histologically proven ovarian cancer were included in the study. All patients 
completed their treatment which included surgery and/or adjuvant chemotherapy. The study 
group consisted of follow-up patients who underwent 18F-FDG PET/CT imaging either after 
abnormal Ca-125 levels.
Total 27 18F-FDG PET/CT imaging were performed in 24 patients. The mean age of the patients 
was 58.3±10.3. The tumor histopathology was derived from epithelial origin in all. 18F-FDG PET/
CT “imaging results were compared with histopathological diagnosis after biopsy or surgical 
procedures following imaging. 
RESULTS:
Residual/recurrent disease was diagnosed histopathologically in 26 of 27 PET/CT scans. PET/CT 
showed positive finding in all residual/recurrence disease . The most common metastasis places 
in PET/CT imaging were the lymph nodes. The involvement areas were abdominal-pelvic lymph 
nodes in 20 (74.1%), thoracic lymph nodes in 4 (14.8%), cervical lymph node in 2 (7.4%), peritoneal 
involvement in 17 (62.9%), and primary tumor areas in 8 (29.6%) PET/CT imaging. When evaluated 
according to histopathological diagnosis, 26 true positive and 1 true negative results were 
obtained in PET/CT. Sensitivity, specificity and accuracy rate for PET/CT were 100%, 100%, 100% 
respectively for the detection of residual/recurrent tissue in the patients with ovarian cancer. 
CONCLUSION:
18F-FDG PET/CT imaging, which helps the clinicians in diagnosis and treatment planning is a 
valuable tool in detection of residual/recurrent disease in the follow-up of patients with ovarian 
cancer whose serum Ca-125 level is rising. 
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Introduction: Osteoporosis is a serious, life-threatening disease in both men and women increases 
with age. This disease is characterized by bone fractures, especially of the spine and hip, although 
any bone can be affected. Calcium is an essential element in the human body and is necessary to 
many cell functions. Adequate intake of calcium is necessary to maintain this balance. Vitamin D 
deficiency is a global health problem and leads to serious problems, can result in low bone mass. 
The effects of vitamin D independent of calcium, magnesium, and phosphate.   
The aim of this study is to characterize the prevalence of vitamin D deficiency and calcium in 
osteoporotic patients.
Material and Methods
As a part of the investigational project 988 participans  were examined of the University Clinical 
Center of Sarajevo, age 20 to 80 during 6 months.  For each patient we did personal history, 
age, DXA, BMI, medications, family history and life style. We have confirmed the presence of 
osteoporosis with a DXA greater than -2.5 SD, the results of vitamin D and calcium levels. Serum 
25(OH) vitamin D and serum Calcium were measured using Rosche Elecsys system on Cobas 
e 601 analyzers at Clinic for Nuclear medicine and Endocrinology and Clinical Chemistry and 
Biochemisty. Referral values for using this method are D vitamin 30,0-50,0 ng/mL and Calcium 
2,10-2,55 mg/L. Osteoporosis was diagnosed based on the bone mineral density (BMD) T-score 
values ≤ -2.5 at the lumbar spine and/or proximal femur measured with dual-energy xray 
absorptiometry (DEXA). 
Results
In investigated group of 988 patients. The frequency of occurrence of osteoporosis is most 
common 44% between the ages of 40-59 years. The patients have a vitamin D deficiency 76% 
and low-normal calcium levels 69 %. We have found the existence of osteoporosis in 73% of the 
female population, compared to men whose osteoporosis occurred only in 27% of cases. Results 
of vitamin D were very low at the beginning of the test and stood at about 14.1 ng/mL, after six 
months of therapy of 800-2000 IU per day amounted to around 42,1 ng/mL. Also the results of 
calcium were low to 6 months of therapy 500-1000 mg daily improvements.
Conclusion(s)
Calcium and vitamin D alone have the ability to prevent bone loss and reduce fracture. Vitamin 
D deficiency is associated with low bone mineral density in patients who have diagnosed 
osteoporosis. The effects of vitamin D independent of calcium, magnesium, phosphate and 
nutrition and have an impact on the incidence of osteoporosis. The prevalence of hypovitaminosis 
D has public health implications, and requires adequate access to the therapy of vitamin D 
supplements, calcium and other minerals. 
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Aim: SBT is an acute well-know condition that causes pain and discomfort in the thyroid and neck. 
However, the degree to which the differences between approaches may be clinically relevant 
has varied across the clinical studies on the topic, and so we wished to further characterize it in a 
population of patients with SAT who have been followed for 40 years.
Material and Methods: We retrospectively reviewed the records of patients with SAT seen at our 
institution since 1978. In total, 416 patient (13% men, 87% woman, age range 28-75 years) with 
citologically proven SAT and negative thyroid peroxidase antibody were enrolled in the study. 
Thyroid morphology and function were analized at various times by hormon testing, Tc-99m 
scintigraphy and ultrasonography (US).
Results - lessons we can learn from the long-term evaluation of SAT:
1. The thyroid can be severely damaged or even destroyed at the same time
leaving patients seriously ill which present significant challenges to physicians treating them.
2. However, patience for patients and physicians is welcome during the SAT.
Even when things seemed to be at their worst the final prognosis is excellent.
3. Getting out of debt is important: the treatment of choice to relieve
acute symptoms are nonsteroidal anti-inflammatory drugs. The treatment with corticosteroids 
extend duration of healing period and increase the recurrent rate of SAT.
4. Triphasic clinical course of transient hyperthyroidism and
hypothyroidism, and return to normal thyroid function is associated with all patients.
5. At the beginning US demonstrated diffuse decreased echogenicity with no
nodular lesion in 16%, diffuse decreased echogenicity with nodular lesion in 34%, and normal 
echogenicity with nodular lesion in 50% of patients.
6. Long-term follow-up showed complete restoration of thyroid in all
patients. 
Conclusion: SAT passes without lasting consequences on thyroid morfology and function.
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In 2015 y officially was marked the beginning of the new era for medical world in the Republic of 
Macedonia. The cyclotron unit became operational and enabled the installation and operation 
of the first public PET/CT scanner. It was the biggest advanced technology investment that has 
ever happened in the field of medical imaging, installation of the cyclotron unit and diagnostic 
unit with hybrid imaging system PET/CT. The investment was done by the government of the 
Republic of Macedonia and the project was realized with the tremendous support of experts 
from the International Atomic Energy Agency (IAEA). By installing the first cyclotron in the region 
the production of short lived radioisotopes become reality. The new developed institution is 
recognized as Public health institution, University institution and fully covers the own needs, also 
have a capacity to cover two private PET/CT units in the Republic of Macedonia and wider Balkan 
area. Establishing a PET/CT and a cyclotron unit together in one building is a very complicated 
project. It takes a lot of time and needs enormous effort dedication, excellent planning with 
expert advice from highly qualified personnel. Nowadays the results of this hard work are visible 
and available to the citizens of the Republic of Macedonia as well as neighboring countries. In 
the paper will be present the results of daily routine quality control of the cyclotron and installed 
sophisticated equipment in radio pharmacy laboratory. Also, diagnostic part is equipped with 
hybrid system such as PET/CT Siemens mCT which combine the powerful PET technology with 
the highly precise X-ray imaging. We are proud that this “state of art” technology we made closer 
to our citizens and we really hope that they will feel the benefit of this new technology in early 
diagnosing but also to avoid unnecessary and costly therapies. Also, a positive impact on the 
overall healthcare budget is also expected.
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Thyroid gland lymphoma makes 1-5% of all malignant thyroid tumors, whereas
Malt lymphoma occurs in about 2-7% of all cases of extranodal lymphoma. 
Chronic lymphocytic thyroiditis is a predisposition for the development of primary lymphoma of 
the thyroid gland.
In the period from 2006 to 2017, a total of 1.909 lobectomy and thyroidectomy has been 
performed at the University Clinical Center of the Republic of Srpska. 
Of the 1.909 patients, only one female patient had a pathologic diagnosis of Malt lymphoma and 
chronic lymphocytic thyroiditis.
We present a case of a female patient with chronic lymphocytic thyroiditis and Malt lymphoma, 
presented by enlargement of the thyroid gland during past year, the dominant left lobe with 
breathing difficulty. 
Preoperatively, a complete diagnostic treatment of the patient within struma of the thyroid gland 
was done without a doubt on tumor changes.
Since the diagnosis of Malt lymphoma in situ was patohistologically diagnosed, the remaining 
diagnostic procedures were made postoperatively to determine the stage of the disease, within 
18F-FDG PET/CT was performed too.
This case report shows extremely rare detection of lymphoma in the thyroid gland, but certainly a 
great caution too about the possibility of lymphoma formation in the area of chronic lymphocytic 
thyroiditis.
Key words: Malt lymphoma, thyroid gland, 18F-FDG PET/CT. 
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Alzheimer’s disease (AD) is a neurodegenerative disorder, which considered the most common 
aetiology of dementia. There are very limited therapeutic applications for AD due to the lack of 
comprehensive understanding of this disease. Several biomarkers for AD have been highlighted; 
however, most of them are common with others neurological disorders. Beta-amyloid plaques 
(ᵦA) & neurofibrillary tangles are the classical biological hallmarks in AD. In fact, the conventional 
diagnostic methods in detecting these changes are risky, challenging and not considered a direct 
indicator of AD. Positron emission tomography imaging, using diverse radiotracers, may provide 
more sensitive and safer way for detecting various functional and molecular changes in AD.
P022
CONTRIBUTION OF FDG PET IMAGING IN THE DETECTION OF UNDERLYING CARCINOMA IN A 
WOMAN WITH NONSPECIFIC MASTITIS
Authors: Oguz Hancerliogulları1, Semra Ince2, Rahman Senocak1, Nuri Arslan2.
E-mail: drsemra@gmail.com
1University of Health Sciences, Gulhane Training and Research Hospital, Department of General 
Surgery, Etlik, Ankara, TURKEY 2University of Health Sciences, Gulhane Training and Research 
Hospital, Department of Nuclear Medicine, Etlik, Ankara, TURKEY
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
Introduction. Differentiation between a malignancy and inflammatory process is still a diagnostic 
challenge. Mammography (MG) and ultrasonography (US) have low sensitivity and specificity in 
dense breasts in order to detect malignancy. On the other hand, malignant mass lesions can also 
be masked on magnetic resonance imaging (MRI) by diffuse inflammatory process.
18-fluorodeoxyglucose positron emission tomography (FDG PET) imaging can be a promising 
alternative imaging method in the evaluation of suspicious breast masses, especially in patients 
with accompanying inflammatory breast diseases. 
Case report. We report an atypical case of a patient suspected for malignancy in right breast on 
physical examination and radiologic findings in favor of mastitis. Neither MG nor US revealed 
any mass lesion consistent with malignancy. Moreover, MRI findings were primarily considered 
as infectious or granulomatous mastitis. However, FDG PET determined the accurate borders of 
tumor and dissemination of breast cancer with superiority to other conventional radiological 
methods. 
Conclusion. This case report emphasizes the contribution of FDG PET imaging to other 
conventional radiological methods with regard to primary tumor diagnosis, determination of the 
biopsy site, and also staging the disease especially in patients with accompanying inflammatory 
breast disease.
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Aim: The aim of this study was to evaluate clinical significance of 18 F-fluorodeoxyglucose ([18 
F]FDG) uptake on positron emission tomography/computed tomography (PET/CT) imaging in 
detecting recurrence or residual disease in patients with colorectal carcinoma (CRC).
Methods: We evaluated 53 lesions in 46 consecutive patients (20 men, 26 women; mean age of 
58.6±10.90; age range: 30–89 years) with FDG PET/CT.
All patients had previous surgery. The main indications for the PET/CT orders were suspicions of 
recurrence (indicated by elevated of CA 19-9 levels (10 cases, %19) or conventional imaging tests 
(17 cases, 32%)) or residual disease (26 cases, %49). The most common site of FDG uptake was 
rectosigmoid (41.5%). All [18 F]FDG uptakes were confirmed by histopathologic or colonoscopic 
findings. 
Results: The sensitivity, specificity, positive predictive value, and negative predictive value of FDG 
PET/CT in the detection of recurrences or residual disease were 100%,51.7%,63.1%, and 100%, 
respectively. In 48.1% of the cases with normal CA 19-9, FDG PET/CT was true positive and in 10% 
of the cases with elevated CA 19-9, FDG PET/CT was true negative. In follow up, conventional 
imaging tests (CT/MRI/US) detected suspicious malignancy in 32%(17/53) of the cases and further 
examination with FDG PET/CT was true negative in 35.2%(6/17).
Conclusion: [18 F]FDG uptake on PET/CT imaging is highly sensitive for both benign and malign 
lesions in patients with CRC. However, FDG PET/CT appears to have great impact especially in 
revealing true negativity of lesions suspected for recurrence or residual disease and thus may 
prevent unnecessary treatments. 
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Somatostatin receptor scintigraphy is known to be highly sensitive for the diagnosis of 
somatostatin expressing neuroendocrine tumors, their regional and distant metastasis. The aim 
of our study was to share our experience in the application of the hybrid imaging techniques 
SPECT-CT and PET–CT in therapy monitoring and their role for the choice of the applied therapy 
in patients with SR-expressing tumors. In total 121 examinations were performed on 45 patients 
before and after 3-6 cycles of therapy (31 of them were examined triple), using the somatostatin 
analog 99mTc-HYNIC-TOC (Tektrotyd,PL) at activity between 370-550 MBq. The average level of 
chromogranin was 221ng/ml and that of Ki 67-19%. Whole body and SPECT-CT scintigraphy were 
performed 2- 4h p.i. In 28/45 of the patients, in whom Ki 67 was above 2%, 18F-FDG PET-CT was 
additionally applied within two weeks.
At initial presentation, the SR scintigraphy with SPECT-CT was only positive in 31/45 of the 
patients, the scintigraphy with PET-CT was only possitive in 6/45 of the patients and in 8/45 the 
result was possituve in both techniques. All patients with positive results were referred for surgery 
or somatostatin therapy and/or chemotherapy depending on the stage and the differentiation 
of the disease. At the follow up, in 10/45 Pts there was a progressin of the disease, in-29-stable 
disease and in 6-regression. As a result of the exams, the therapy was modified or change in 62% / 
28/45 of the patients /. In summary, we suggest that the use of SPECT-CT and PET-CT can help to 
reliebly choose the individual therapy of the patient with simatostatin expressing tumors and to 
follow its effect.
P025
DEVELOPMENT OF THE METHOD FOR BIO-ANALYSIS OF 68GA-PSMA-11 IN PATIENT BLOOD 
Author: Aljoša Stanković
E-mail: aljosa.stankovic@gmail.com
University clinical centre of the Republic of Srpska/Banja Luka/Bosnia and Herzegovina
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
Purpose
The aim of the study was to optimize the Solid Phase Extraction (SPE) combined with UPLC 
method for bio-analysis of [68Ga]-PSMA-11 in patient blood and to make validated protocol. The 
developed method would be used for construction of pharmacokinetic model of [68Ga]-Ga-
PSMA-11 and its formed metabolites in blood. 
Material and Methods
For development of SPE and UPLC method plasma from 4 different patients was collected. 
Trapping efficiency was tested between Sep-Pak and Waters OASIS cartridge. Optimization of 
the elution step with different pH of the sample, different solutions and pH of the solutions was 
performed. For development of UPLC method, C18 and 5µm columns with different length were 
tested. The solvents (water + 0.1% TFA and acetonitrile + 0.1%TFA) in gradient UPLC method were 
optimized. Elution fractions were collected with fraction collector (0.5 min) and measured in the 
well counter. Both recoveries of SPE and UPLC were calculated. 
Results
Waters OASIS 6cc cartridge showed the best performance for efficient trapping of [68Ga]-
PSMA-11. Acidification of 70% ethanol with 200 µl 1M HCl improves elution step and acidification 
of the sample helps to minimize the activity in wash and waste step. The best results were 
obtained with
C18 4.6x250mm 5µm column. The highest activity of elution fractions were measured at 
the retention time of 7.5–8.0 min. Recoveries from SPE and UPLC were 94.44% and 112.61% 
respectively.
Conclusions
The optimized SPE and UPLC methods proved to be good method to separate and identify the 
compound [68Ga]-PSMA-11 from the complex blood matrix. With the retention time of 7-8 min, 
which is in accordance with cold Ga-PSMA-11/PSMA-11, [68Ga]-PSMA-11 could be identified. 
These results are promising for further analysis of [68Ga]-PSMA-11 in patient blood, taken in 
definite time points after injection.
Key words: [68Ga]-PSMA-11, Solid Phase Extraction, UPLC
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PURPOSE:
To evaluate the efficacy of F-18 FDG PET/CT in solitary fibrous adenoma. 
CASE:
A 64-years old woman was admitted to the hospital for shortness of breath, fever and cough. On 
chest examination, breath sounds were absent on the right hemithorax. The plain chest X-ray 
showed the presence of a giant mass in the right hemithorax. Contrast-enhanced Computed 
Tomography scan showed a large mass in right hemithorax. Then F-18 FDG PET/CT was 
performed and the well-demarcated lesion pushing mediastinum to the left in the covering right 
hemithorax was appeared heterogenous increased metabolic activity (SUVmax=6.1). The patient 
underwent a thoracotomy and it was successfully resected totally. The pathological diagnosis of 
the tumor was localized fibrous tumor of the mediastinum. 
DISCUSSION:
Solitary fibrous tumor of mediastinum is a rare neoplasm. In the literature; although both benign 
and malignant solitary fibrous tumors with low FDG uptake have been reported, there are also 
malignant cases with high
F-18 FDG uptake. In this study, PET/CT images showed high uptake in the tumor and 
histopathological findings are showed that three malignant
criteria: massive tumor measuring, greater cellularity, necrosis.
CONCLUSION: 
F-18 FDG PET/CT may provide an information on the solitary fibrous tumor by giving both 
functional and morphological imaging data in the pre-operative period .
Keywords: F-18 FDG, PET/CT, solitary fibrous tumor, mediastinum.
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Introduction: Regional changes of brain metabolism measured with 18F-FDG PET/CT (FDG/
PET) can help in differentiation of neurodegenerative parkinsonian syndromes. Based on 
network analysis FDG/PET brain studies performed in patients with different neurodegenerative 
parkinsonisms using specific network analysis called scaled subprofile model/principal 
component analysis (SSM/PCA), different metabolic brain patterns specific for each parkinsonian 
syndrome were identified - among them Parkinson disease related pattern (PDRP), multiple 
systemic atrophy related pattern (MSARP) and progressive supranuclear palsy related pattern 
(PSPRP).
Expression of these patterns can be calculated prospectively for any FDG/PET brain study using 
Topographic Profile Rating (TPR) analysis.
Aim: To present a patient with parkinsonism with atypical clinical presentation and the 
contribution of FDG/PET brain studies in clinical diagnostics.
Patient and methods: In 52 years old parkinsonian male patient with atypical clinical presentation 
in whom the possible multiple system atrophy was diagnosed, FDG/PET brain imaging was 
performed. Visual reading and Statistical Parametric Mapping analysis were consistent with 
idiopathic Parkinson’s disease (PD), mostly due to hyperactive basal ganglia. Since atypical 
parkinsonian syndrome was suspected we used TPR analysis to calculate the expression of PDRP, 
MSARP and PSPRP. 
Results: PDRP expression was high and MSARP and PSPRP were low compare to normal. 
Furthermore, we used previously developed logistic algorithm to calculate probability of specific 
disease; probability for Parkinson’s disease was over 93% compared to atypical parkinsonian 
syndromes with probability of less than 7%. 
Six years after the disease onset and few months after FDG/PET brain study patient died due to 
cardiorespiratory arrest. Post-mortem pathohistological examination was consistent with the 
idiopathic Parkinsons’s disease.
Conclusion: Functional brain imaging with FDG/PET may be helpful in diagnosing and 
differentiating among parkinsonian syndromes. Implementation of PDRP as well as other disease 
specific brain network patterns into clinical practice may significantly improve the accuracy of the 
early diagnosis of parkinsonian syndromes.
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Objective: Primary central nervous system (CNS) lymphoma is an aggressive and fatal extranodal 
non-Hodgkin lymphoma (NHL) confined to CNS at initial diagnosis. It has a poor prognosis and 
fatal outcome according to systemic NHL. Until now, a lot of baseline risk factors like serum 
lactate dehydrogenase (LDH) level, age, Karnofsky performance score (KPS), involvement of 
deep brain structures (DBS), cerebrospinal fluid protein concentration and many scoring systems 
consisting of them have been stated to estimate the prognosis. FDG-PET/CT has a high prognostic 
value with respect to overall survival (OS) and disease-free survival (DFS) in many cancers and 
lymphomas. We studied to evaluate the role of metabolic tumor parameters derived from primary 
staging FDG-PET/CT for prognosis estimation in primary CNS lymphoma.
Material and Methods: 12 patients having primary CNS lymphoma of diffuse large B-cell type 
(stage I disease) were included in this retrospective cohort study. Primary staging FDG-PET/CT 
were performed and quantitative parameters of maximum standardized uptake value (SUVmax), 
average standardized uptake value (SUVmean), metabolic tumor volume (MTV) and total lesion 
glycolysis (TLG) were calculated for all patients before the treatment. Cox regression analysis was 
used to examine the related factors with survival time.
Results: There were 5 male and 7 female patients. Mean age of the patients was 56 years. Mean 
OS and DFS were 21 and 13 months, respectively. Mean SUVmax, SUVmean, MTV and TLG were 
19.2±4.5, 10±3.2, 48±15 cm3 and 510±170, respectively. After the analysis of all potential risk 
factors effecting recurrence/metastasis (age, sex, serum LDH, involvement of DBS, SUVmax, 
SUVmean, MTV, TLG) with univariate analysis; TLG remained statistically significant (p=0.03).
Conclusion: Although all metabolic tumor parameters are helpful in prognosis estimation of 
primary CNS lymphomas, TLG is the most important one of them and may play a role in patient 
management.
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The present study was conducted to investigate the role of total body metabolic tumor volume 
(MTV, mm3 ) and total lesion glycolysis (TLG) values obtained by PET/CT imaging for predicting 
metabolic abnormalities in newly diagnosed cancer patients. Patients having solid tumors with 
initial PET/CT staging were evaluated in a prospective cohort study. MTV and TLG values of all 
patients were measured beside SUV values as PET/CT parameters. Initial metabolic status of 
patients was evaluated based on basal metabolic rates, serum vitamin, mineral, and biochemical 
metabolite levels and antioxidant enzyme capacities. The MTV and TLG levels revealed significant 
relationships with cancer-induced metabolic abnormalities as high BMR and LDH, and low 
albumin levels as well as advanced stage and presence of metastasis (p<0.05). Cut-off values and 
sensitivity and specificity rates in terms of high BMR (>20 Kcal/kg) were obtained to be >52400 
mm3 for MTV (0.84 and 0.63) and >274208 for TLG (0.84 and 0.63). The same values for high LDH 
were  219520 mm3 (0.52 and 0.88) for MTV and  411792 (0.78 and 0.58) for TLG, respectively. 
The values for low albumin levels were 89520 mm3 (0.63 and 0.10) for MTV, and  887840 
(0.75 and 1.00 ) for TLG, respectively. In conclusion, MTV and TLG cut-off values determined by 
ROC analysis can predict metabolic abnormalities in initial BMR, LDH and albumin levels with 
high specificity and sensitivity. It was recommended to test MTV and TLG levels to determine 
initial metabolic status of diverse clinically significant patient groups with various cancer types. 
Keywords: MTV, TLG, BMR, Metabolic abnormality, Cancer
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Objective. The purpose of this study was to evaluate damage of the kidney with technetium-99m- 
dimercaptosuccinic acid (99mTc-DMSA) scintigraphy in children with congenital hydronephrosis 
(CH) and the influence of other postnatal associated diagnoses on abnormal 99mTc-DMSA 
findings. Subjects and Methods. 99mTc-DMSA scintigraphy in 54 children (17 girls and 37 boys), 
aged from 2 months to 5 years (median 11 months) with 66 congenital hydronephrotic renal units 
(RU) (42 unilateral hydronephrosis-29 boys and 13 girls; 12 bilateral hydronephrosis-8 boys and 4 
girls) was performed. Male/female ratio was 2,2: 1, unilateral/bilateral hydronephrosis ratio was 4:1. 
Hydronephrosis classified into three groups according to ultrasound measurement of the antero-
posterior pelvic diameter APD): mild (APD 5-9.9mm) was present in 13/66RU, moderate (APD 10-
14.9mm) in 25/66RU, and severe (APD ≥15mm) in 28/66RU. Simple hydronephrosis was present 
in 15RU, and the postnatal associated clinical diagnosis were vesicoureteric reflux (VUR) in 21, 
pelviureteric junction (PUJ) obstruction in 7, pyelon et ureter duplex in 11, megaureter in 11 and 
posterior urethra valves in 1RU, respectively. Static renal scintigraphy was performed 2 to 3 hours 
after intravenous (iv) injection of 99mTc-DMSA using a dose of 50μCi/kg (1.85MBq/kg; minimal 
dose: 300μCi). Four views (posterior, left and right posterior oblique and anterior) were obtained 
with a head gamma camera “Orbiter” filtered with high resolution parallel whole collimator. All 
images were stored in an Pegasys computer with a matrix size of 256×256. The relative kidney 
uptake (RKU) between the left and right kidney was calculated as an average number counts 
from anterior and posterior view. Renal pathology was defined as inhomogenous or focal/
multifocal uptake defects of radiopharmaceutical in hydronephrotic kidney or as split renal 
uptake of <40%, and poor kidney function was defined as split renal uptake <10%. Descriptive 
and analytical statistics (SPSS version 20.0) was performed. Analytical statistics implied the non-
parametric Mann-Whitney test for determination of statistically significant difference between 
the normal and pathological findings on 99mTc-DMS scan. The default level of significance 
was P<0.05. Results: Our 99mTc-DMSA scintigraphy findings in children with ANH were: decreased 
or enlarged kidney with inhomogeneous kidney uptake radiopharmaceutical in 22, irregular 
shape kidney with inhomogeneous accumulation of radiopharmaceutical in 3, connected (fused) 
kidney in 1 patient, and poorly or nonvisual kidney in 14RU respectively (total 40/66RU with 
pathological 99mTc-DMSA finding, 60,6%). Relative accumulation in hydronephrotic kidney was 
less or equal to 40% in 17RU, less than 10% in 14RU and inhomogeneous radiopharmaceutical 
uptake with relative accumulation over 40% was detected in 9RU. Regular kidney morphology 
with homogeneous accumulation of radiopharmaceutical (normal DMSA scintigraphy finding) 
were found in 26/66RU (39,4%). Statistically significant correlation between the degree of the 
hydronephrosis (APD) and 99mTc-DMSA scan findings (P<0.001) and between the degree of the 
VUR and DMSA scan finding (P=0.002) was established. In our study, other associated diagnosis 
were not statistically correlated with pathological findings on 99mTc-DMSA scan due to low 
number of patients. Conclusion: On the basis of these results (60% pathological findings) we 
recommend DMSA scintigraphy in the evaluation renal pathology in children with congenital 
hydronephrosis. Greater number of patients is needed for the estimation of the associated 
diagnosis (other than VUR) influence on the renal parenchymal damage in children with CH.
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Objective Cancer is an important health problem.Early detection of cancer has great importance 
in preventing mortality and morbidity linked to cancer.The aim of this study is to compare the 
quantitative value of SUVmax obtained from F-18 FDG PET/CT imaging of oncology patients with 
the cell free DNA (cfDNA) amounts measured in plasma of patients and thus research whether 
cfDNA is a significant marker to identify the presence of malignancy in the early period.
Materials and methods The study was prospective and began after receiving ethics committee 
permission from our center.The clinical situation, histopathologic, laboratory and treatment 
parameters were investigated from patient files.SUV max and cfDNA quantities were assessed 
using the Mann–Whitney U-test and clinical characteristic analysis.
Results A total of 184 patients (87% female, 47.3% male, 97% male) were included in the study 
group,ranging in age from 25 to 89 years with a mean age of 53.38 ± 17.98 years.There was no 
statistically significant difference in plasma cfDNAvalues between patient and control group. As a 
result of the comparison of SUVmax and cfDNA values in the study, there was a weak correlation 
between SUV max and cfDNA (r = 0,140; p = 0,059).
Conclusion In researching the response of cancer to early diagnosis and treatment, no diagnostic 
method is sufficient alone.There is a need for comparison of cfDNA levels obtained from plasma 
and quantitative parameters from PET/CT images of oncology patients in more detailed advanced 
studies with larger patient series.
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Introduction: The aim of this study was to identify tumor characteristics of primary malignant 
melanoma predictive of sentinel lymph node (SLN) positive status and to determine whether 
sentinel lymph node status has an impact on disease recurrence and survival period. 
Material and Methods: 80 patients (50±19 years; average Breslow score 1,9 mm; 33 males - 41,25% 
and 47 females – 58,75%) with primary malignant melanoma, staged T1b/T2 (1-4mm Breslow 
score) N0, M0 were analyzed. Univariate and multivariate analyses were performed to assess 
factors that predict SLN positive status, recurrence and survival period.
Results: We identified Breslow’s thickness, Clark level, ulceration, lymphocytic infiltration and 
colloid uptake of SLN as independent predictors of SLN status. SLN status was a significant 
predictor of disease free survival. 
Conclusion: Our study confirms Breslow’s thickness, Clark level, ulceration, tumor lymphocytic 
infiltration and colloid uptake of SLN as factors predictive of SLN metastasis in cutaneous 
melanoma patients. We also confirmed SLN status to be the most significant independent 
predictor of disease free survival and risk of regional recurrence.
Key words: prognostic factors, recurrence rate, melanoma, sentinel lymph node biopsy.
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Purpose
The aim of the paper is to show the correlation of the TIRADS score and the pathohistological 
findings of thyroid tissue. The combined TIRADS score with scintigraphic thyroid gland 
enlargement increases its sensitivity and specificity, as well as the positive and negative predictive 
value.
Materials and methods
A total of 50 patients with thyroid gland cancer have been included. All patients had hormonal 
status, antibody status, thyroid ultrasound, scintigraphy of the thyroid gland as well as fine-needle 
aspiration cytology (FNAC) . Evaluation of TIRADS promptly showed a recommendation for 
FNAC. Cytology has shown the presence or the possibility of the presence of thyroid cancer. After 
surgery, a suspicion of thyroid cancer has been confirmed.
Results
A total of 50 patients were analyzed. Of these, 40 (75.5%) are women, while 10 are men (18.9%). 
The age of the respondents is at least 29 years old when diagnosing the cancer, while it is 
maximum 85 years. There is no statistically significant difference in the incidence of cancer 
between males and females (94.3% vs 5.7%) [χ2 (10) = 0.332; P> 0.05]. The most common is the 
papillary carcinoma witch was found in 28 patients (52.8%), while follicular carcinoma was found 
in 15 patients (28.3%). This difference is statistically significant (52.8% vs. 28.3%). Of the total 
number of confirmed thyroid carcinoma, TIRADS score showed 44 (88%) positive findings referring 
to thyroid cancer. This difference is not statistically significant [χ2 (44) = 0.748; P> 0.05]. Of the total 
number of patients, the scintigraphic finding showed a positive finding in 45
(84.9%) patients, while in 5 (9.4%) patients findings were negative. This difference is not statistically 
significant [χ2 (50) = 0.109; P> 0.05].
Sensitivity of TIRAD is 75.6%, while the specificity is 60.0%. The positive predictive value is 94.4%, 
while the negative predictive value is 21.4%.
The sensitivity of the scintigraphy is 93.3%, while the specificity is 40.0%. The positive predictive 
value is 93.3%, while the negative predictive value is 40.4%
Conclusion
The analysis showed that the TIRADS score associated with the finding of scintigraphy can show 
suspicion of thyroid cancer. A pathohistological finding has confirmed the suspicion of cancer.
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Purpose
The aim of the paper is to show the correlation of the TIRADS score and the pathohistological 
findings of thyroid tissue. The combined TIRADS score with scintigraphic thyroid gland 
enlargement increases its sensitivity and specificity, as well as the positive and negative predictive 
value.
Materials and methods
A total of 50 patients with thyroid gland cancer have been included. All patients had hormonal 
status, antibody status, thyroid ultrasound, scintigraphy of the thyroid gland as well as fine-needle 
aspiration cytology (FNAC) . Evaluation  of TIRADS promptly showed a recommendation for 
FNAC. Cytology has shown the presence or the possibility of the presence of thyroid cancer. After 
surgery, a suspicion of thyroid cancer has been confirmed.
Results
A total of 50 patients were analyzed. Of these, 40 (75.5%)  are women, while  10 are men 
(18.9%). The age of the respondents is at least 29 years old when diagnosing the cancer, while 
it is maximum 85 years. There is no statistically significant difference in the incidence of cancer 
between males and females (94.3% vs 5.7%) [χ2 (10) = 0.332; P> 0.05]. The most common is the 
papillary carcinoma witch was found in 28 patients (52.8%), while follicular carcinoma was found 
in 15 patients (28.3%). This difference is statistically significant (52.8% vs. 28.3%). Of the total 
number of confirmed thyroid carcinoma, TIRADS score showed 44 (88%) positive findings referring 
to thyroid cancer. This difference is not statistically significant [χ2 (44) = 0.748; P> 0.05]. Of the total 
number of patients, the scintigraphic finding showed a positive finding in 45 (84.9%) patients, 
while in 5 (9.4%) patients findings were negative. This difference is not statistically significant 
[χ2 (50) = 0.109; P> 0.05]. Sensitivity of TIRAD is 75.6%, while the specificity is 60.0%. The positive 
predictive value is 94.4%, while the negative predictive value is 21.4%. The sensitivity of the 
scintigraphy is 93.3%, while the specificity is 40.0%. The positive predictive value is 93.3%, while 
the negative predictive value is 40.4%
Conclusion
The analysis showed that the TIRADS score associated with the finding of scintigraphy can show 
suspicion of thyroid cancer. A pathohistological finding has confirmed the suspicion of cancer.
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Diagnosis of Parkinson’s disease and essential tremor is obliged. Many diagnostic tests cannot 
truly differentiate Parkinson’s disease essential tremor. Radiopharmacutical indicated for striatal 
dopamine transporter visualization using single photon emission computed tomography brain 
imaging to assist in the evaluation of adults with suspected Parkinsonian syndrome. The aim of 
this abstract is to present technologist experience in performing DaTscan study. Before setting 
up protocol we checked image quality with Anthropomorphic Head Phantom for DaTscan. 
We performed DaTscan on 17 patients: 10 female and 7 male patients. Every patient had been 
scanned with the same protocol our Clinic use: IV application in the range of 111 - 185 MBq I-123 
Ioflupane, scanning time is 3-6 hours after application, distance between the detectors was 13-
15 cm. Patient position is supine with head towards detectors. Scanning method is SPECT with 
FANBEAM collimators. Scanning duration is 30 secs per view. Number of views 60 with zoom of 
1,23. Image matrix size is 128x128, energy window 159 keV. Every patient is prepared with thyroid 
blocking with potassium iodide oral solution or Lugol’s Solution or potassium perchlorate 400 
mg at least one hour before application. We included DaTscan in our routine clinical work. Our 
protocol is in accordance with European guidelines. Quality control showed good image quality 
for our physicians and referring physicians showed approval for DaTscan findings in Parkinson’s 
diagnostic algorithm. After initial phase there has been increased interest in this diagnostic 
modality. 
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Introduction: As powerful and non-destructive techniques, Attenuated total reflectance-infrared 
(ATR-IR) and Raman spectroscopy provide valuable molecular structure information and are 
convenient for verification of any changes in the native state of proteins. The purpose of this 
experimental work is to determine the secondary structure of trastuzumab after conjugation with 
(p-SCN-Bn-1B4M-DTPA (2-(4-isothiocyanatobenzyl)-6-methyl-diethylene-triaminepentaacetic 
acid) and p-SCN-Bn-DTPA (2-(4-izothiocyanatobenzyl)-diethylenetriaminepentaacetic acid)) by 
applying of these two techniques.  
Material and methods: The 10- and 50-fold molar excess of chelators were conjugated with pure 
trastuzumab and freeze dried to solid state. Vibrational spectroscopy (Raman and ATR-IR) was 
applied for further physico-chemical examinations of lyophilized non-labeled samples by directly 
applying under the laser beam of the instrument. The spectra of conjugated samples were 
compared with naked trastuzumab purified from commercial product Herceptin®.  
Results: The presence of characteristic amide bands (amide I, II and III bands) in ATR-IR and Raman 
spectra have indicated of retained native IgG1 structure of the antibody principally composed 
of β-sheets. The same as pure antibody, Raman spectra of conjugates contain the characteristic 
amide I band at ~1670 cm-1 and amide III band (1230-1300 cm-1). IR spectra of the samples also 
correspond with naked antibody and contain the amide I (1700-1600 cm-1), amide II (1480-1575 
cm-1) and amide III bands (1255-1244 cm-1) specific for secondary structure of the proteins. 
Conclusion: No integrity changes, physicochemical and structural modifications of trastuzumab 
after conjugation approve retained β-sheet structure of the antibody and support the opportunity 
for further development of radioimmunotherapeutics and diagnostic products active against 
HER2 positive breast tumors. 
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Welcome to Sarajevo, capital and the largest city of Bosnia and Herzegovina !
Sarajevo is a city in which even strangers can feel like home. Neither geographically expansive, nor 
characterised by large buildings, the city retains a particular, arresting charm with its abundance of 
busy cafés and abiding tradition of hospitality.
The city’s breathtaking backdrop of seemingly endless hills and towering mountains have in a 
sense always isolated the city, creating a timeless world, which despite its seclusion has always 
kept its doors open to the rest of the world. Although Sarajevo is a capital city typied by the 
hustle and bustle of everyday life, it also possesses a unique ambience that seeps into the soul.
This city epitomizes a partial centuries-old struggle against outside inuences combined with the 
absorption of these inuences into one of the most diverse cultures in Europe. Indeed, few places 
on earth feature an Orthodox and a Catholic church, a mosque and a synagogue within easy 
walking distance of each other. If there were any city in Europe that eortlessly straddles east and 
west, it is Sarajevo. Here the Byzantine and Ottoman empires of the east and the Roman, Venetian 
and Austro-Hungarian empires of the west left an indelible mark through culture, traditions and 
religions. A walk through Sarajevo is a walk through its past. From the oriental Ottoman quarters 
lined with sweet shops, cafés and handicraft workshops, to the administrative and cultural centre 
of Austro-Hungarian times, Sarajevo encompasses the very best of both worlds. In Sarajevo, peo-
ple have time for family and friends. It is often said that a man’s wealth here is not measured in his 
material belongings but rather in his friendships.
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